References
- Cai RH, Xiao CY, Guan J, Zhao YQ. 2008. Study on hypoglycemic effect of Momordica Charantia saponins. Chin Tradit Herbal Drugs. 39(5):111–112.
- Chao CY, Sung PJ, Wang WH, Kuo YH. 2014. Anti-inflammatory effect of Momordica charantia in sepsis mice. Molecules. 19(8):12777–12788.
- Chen WH. 2010. High yield cultivation techniques of Momordica charantia. Seed World. 10:53.
- Chen F, Huang G, Huang H. 2021. Preparation, analysis, antioxidant activities in vivo of phosphorylated polysaccharide from Momordica charantia. Carbohydr Polym. 252:117179.
- Chen F, Huang G, Yang Z, Hou Y. 2019. Antioxidant activity of Momordica charantia polysaccharide and its derivatives. Int J Biol Macromol. 138:673–680.
- Cortez-Navarrete M, Martínez-Abundis E, Pérez-Rubio KG, González-Ortiz M, Méndez-Del Villar M. 2018. Momordica charantia Administration improves insulin secretion in type 2 diabetes mellitus. J Med Food. 21(7):672–677.
- Fang EF, Ng TB. 2011. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med. 11(5):417–436.
- Jia S, Shen M, Zhang F, Xie J. 2017. Recent advances in Momordica charantia: functional components and biological activities. IJMS. 18(12):2555.
- Peter EL, Kasali FM, Deyno S, Mtewa A, Nagendrappa PB, Tolo CU, Ogwang PE, Sesaazi D. 2019. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: systematic review and meta-analysis. J Ethnopharmacol. 231:311–324.
- Sun Y, Sun F, Li J, Wu M, Fan X, Meng Y, Meng Y. 2016. Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, identification and anti-tumor activity. Molecules. 21(11):1457.
- Zeng Y, Guan M, Li C, Xu L, Zheng Z, Li J, Xue Y. 2018. Bitter melon (Momordica charantia) attenuates atherosclerosis in apo-E knock-out mice possibly through reducing triglyceride and anti-inflammation. Lipids Health Dis. 17(1):251.
- Zhang DD, Chen YQ, Xie X, Liu JL, Wang QJ, Kong W, Zhu Y. 2012. Homocysteine activates vascular smooth muscle cells by DNA demethylation of platelet-derived growth factor in endothelial cells. J Mol Cell Cardiol. 53(4):487–496.
- Zhang M, Li F, Wang X, Gong J, Xian Y, Wang G, Zheng Z, Shang C, Wang B, He Y, et al. 2020. MiR145 alleviates Hcyinduced VSMC proliferation, migration, and phenotypic switch through repression of the PI3K/Akt/mTOR Pathway. Histochem Cell Biol. 153(5):357–366.